Granted Patent
B2
US 7,635,753 · App. 12/033,229 · Granted Dec 22, 2009
Prostate cancer and melanoma antigens
Assignee:
Wisconsin Alumni Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods for identifying a human subject as a candidate for further prostate cancer or melanoma examination are disclosed. Also disclosed are methods for determining whether an immune therapy has elicited a tumor-specific immune response in a prostate cancer or melanoma patient. Further disclosed are kits that can be used to practice the above methods. Methods for identifying candidate compounds for further testing as preventive or therapeutic agents for melanoma are also disclosed.
Claims (4)
1. A kit comprising:
a first polypeptide that comprises MAD-Pro-30 (SEQ ID NO: 58);
a second polypeptide that comprises androgen receptor (AR) ligand binding domain (SEQ ID NO: 59); and
a third polypeptide that comprises MAD-Pro-22 (PSA) (SEQ ID NO: 57).
Assignments (2)
CONFIRMATORY LICENSE
Recorded Apr 2, 2010
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024179/0744 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 28, 2009
From: MCNEEL, DOUGLAS G.; DUNPHY, EDWARD J.; DUBOVSKY, JASON A.; HOEPPNER, LUKE H.
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 022168/0440 →
Continuity (2)
Provisional Application
6089059000
· Feb 19, 2007